Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study

References

• Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, . Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002;33:459–65.
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1–12.
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, Meyer M, Müller M, Druker BJ, . Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100–4.
   PubMed Web of Science ®Google Scholar
• Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567–72.
   PubMed Web of Science ®Google Scholar
• Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999;154:53–60.
   PubMed Web of Science ®Google Scholar
• Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A, . Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000;157:1091–5.
   PubMed Web of Science ®Google Scholar
• Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, . KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156: 791–5.
   PubMed Web of Science ®Google Scholar
• Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF Jr. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999;18:1897–902.
   PubMed Web of Science ®Google Scholar
• Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Matsuda H, . Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999;59:4297–300.
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279: 577–80.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, . PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299: 708–10.
   PubMed Web of Science ®Google Scholar
• Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, . Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660–7.
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, . Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139–45.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–6.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925–32.
   PubMed Web of Science ®Google Scholar
• Okuda K, Weisberg E, Gilliland G, Griffin D. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97: 2440–8.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, . Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344: 1052–6.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, . Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26:620–5.
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472–80.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, . Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342–9.
   PubMed Web of Science ®Google Scholar
• Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, . Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626–32.
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 2004;364:1127–34.
   PubMed Web of Science ®Google Scholar
• Casali PG, Verweij J, Kotasek D, LeCesne A, Reichardt P, Blay JY, . Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): Survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patients. Eur J Cancer 2005;3:201(abstr 711).
   Google Scholar
• Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, van Oosterom AT, . KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42: 1093–103.
   PubMed Web of Science ®Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: A meta-analysis of 1,640 patients. J Clin Oncol 2010;28:1247–53.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Center. Clinical practice guidelines in oncology. Soft tissue sarcoma. V.2.2010.http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf
   Google Scholar
• Casali PG, Blay JY. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v98–102.
   PubMed Web of Science ®Google Scholar
• Du CY, Shi YQ, Zhou Y, Fu H, Zhao G. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST). J Surg Oncol 2008;98:175–8.
   PubMed Web of Science ®Google Scholar
• Kim TW, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, . Kinase mutations and efficacy of imatinib in Korean patients with advanced gastrointestinal stromal tumors. Oncologist 2009;14:540–7.
   PubMedGoogle Scholar
• Yeh CN, Chen TW, Lee HL, Liu YY, Chao TC, Hwang TL, . Kinase mutations and imatinib mesylate response for 64 Taiwanese with advanced GIST: Preliminary experience from Chang Gung Memorial Hospital. Ann Surg Oncol 2007;14:1123–8.
   PubMedGoogle Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
   PubMed Web of Science ®Google Scholar
• Ryu MH, Lee JL, Chang HM, Kim TW, Kang HJ, Sohn HJ, . Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol 2006;36:17–24.
   PubMedGoogle Scholar
• Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: Misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 2006;79:e40–4.
   PubMedGoogle Scholar
• Shankar S, van Sonnenberg E, Desai J, Dipiro PJ, van Den Abbeele A, Demetri GD. Gastrointestinal stromal tumor: New nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005;235: 892–8.
   PubMed Web of Science ®Google Scholar
• Kang DY, Park CK, Choi JS, Jin SY, Kim HJ, Joo M, . Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol 2007;31:224–32.
   PubMedGoogle Scholar
• Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, . Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004; 10:3076–81.
   PubMedGoogle Scholar
• Keun PC, Lee EJ, Kim M, Lim HY, Choi DI, Noh JH, . Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg 2008; 247:1011–8.
   PubMedGoogle Scholar
• Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, . Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360–7.
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, . Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 2008;26:5352–9.
   PubMed Web of Science ®Google Scholar
• Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, . Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005;23:5795–804.
   PubMed Web of Science ®Google Scholar